Roche's Breakthrough: Cancer Treatment Moving Home, Slashing Costs by 80% as EU Panel Approves

CHMP endorses Roche’s Phesgo for administration out of clinical settings

This fixed-dose combo of Perjeta (pertuzumab) and Herceptin (trastuzumab), delivered via SC injection along with intravenous chemotherapy, offers a subcutaneous (SC) treatment option for human epidermal growth factor The post CHMP endorses Roche’s breast cancer therapy for administration out of clinical settings appeared first on Pharmaceutical Business review.

CHMP Recommends Approval of At-Home, Subcutaneous Trastuzumab/Pertuzumab in HER2+ Breast Cancer

The EMA’s CHMP has recommended at-home administration of pertuzumab, trastuzumab and hyaluronidase combination therapy for HER2+ breast cancer.

Roche's Breakthrough: Cancer Treatment Moving Home, Slashing Costs by 80% as EU Panel Approves

CHMP endorses Phesgo for at-home breast cancer treatment, promising 80% cost reduction and improved patient experience. See impact analysis.